Breaking News Instant updates and real-time market news.

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23

Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies

Allergan and Molecular Partners announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with neovascular age-related macular degeneration, or nAMD. In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab. These data were presented as a late-breaking oral presentation during Retina Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology, or AAO. Through week 104, patients received Abicipar 2 mg every 8-weeks or every 12-weeks or ranibizumab 0.5 mg every 4 weeks. At week 104 in the pooled Phase 3 data, the proportion of patients with stable vision was 93%, 90% and 94% in 8-week Abicipar; 12-week Abicipar and 4-week ranibizumab treatment regimens, respectively. This continuation of stable vision in year 2 further reinforces the ability of Abicipar to deliver consistent quarterly dosing for the majority of patients. "Current anti-VEGF treatments for neovascular age-related macular degeneration require frequent intravitreal injections," said Rahul N. Khurana, M.D., Northern California Retina Vitreous Associates Medical Group. "Based on the results of CEDAR and SEQUOIA, which reinforce the efficacy of Abicipar while decreasing the number of injections, Abicipar could transform anti-VEGF treatment regimens."

AGN Allergan
$169.06

1.255 (0.75%)

09/12/19
UBSW
09/12/19
NO CHANGE
Target $189
UBSW
Buy
Allergan price target raised to $189 from $172 at UBS
UBS analyst Navin Jacob, who this morning upgraded AbbVie (ABBV) to Buy from Neutral, raised his price target on Allergan (AGN) shares to $189 from $172 based on the two companies' deal terms and his revised AbbVie price target of $79. He expects the AbbVie deal to close in the first quarter of 2020, stating that he believes the two have sufficiently addressed possible anti-trust issues with the divestitures of Zenpep and Creon. Jacob keeps a Buy rating on Allergan shares.
09/24/19
ADAM
09/24/19
NO CHANGE
Target $13
ADAM
Buy
Sientra valuation offers compelling risk/reward, says Canaccord
Canaccord analyst Kyle Rose believes the current valuation of Sientra (SIEN) offers a compelling risk/reward as the set up into Q3 and Q4 appears to be positive. The analyst believes its improving inventory position and major recall from market leader Allergan (AGN) should serve to accelerate the share taking opportunity in the breast implant market. Rose reiterated his Buy rating and $13 price target on Sientra shares.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
09/30/19
WELS
09/30/19
NO CHANGE
Target $184
WELS
Outperform
Allergan price target raised to $184 from $176 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Allergan (AGN) to $184 from $176 as the company is in the process of being acquired by AbbVie (ABBV) and to account for the change in the latter's stock price from the proposed deal. Despite the FTC's second request, he does not believe there is a significant risk of the deal not being finalized given the little overlap there is between the companies. The analyst reiterates an Outperform rating on Allergan's shares as he likes standalone Allergan shares, and believes the current deal spread is attractive.

TODAY'S FREE FLY STORIES

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

17:36
11/11/19
11/11
17:36
11/11/19
17:36
Earnings
Hudbay Minerals reports Q3 EPS ($1.05), consensus 18cc »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Earnings
Fluent reports Q3 EPS (1c), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

MDGL

Madrigal Pharmaceuticals

$103.57

0.78 (0.76%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Hot Stocks
Madrigal announces publication of 'positive' Phase 2 results for resmetirom »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KINS

Kingstone Companies

$8.72

-0.04 (-0.46%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kingstone Companies reports Q3 EPS (23c), two estimates 28c »

Reports Q3 net written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kemet sees Q3 revenue down 8%-13% sequentially, consensus $323.97M »

CEO, William Lowe Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:31
11/11/19
11/11
17:31
11/11/19
17:31
Earnings
Kemet reports Q2 adjusted EPS 66c, consensus 66c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NTZ

Natuzzi

$1.70

0.1 (6.25%)

17:21
11/11/19
11/11
17:21
11/11/19
17:21
Hot Stocks
Natuzzi Chief Commercial Officer Nazzario Pozzi departs »

Natuzzi announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:18
11/11/19
11/11
17:18
11/11/19
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:17
11/11/19
11/11
17:17
11/11/19
17:17
Earnings
UGI Corporation reports Q4 EPS (27c), consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

, GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

17:05
11/11/19
11/11
17:05
11/11/19
17:05
Periodicals
State AGs gather in Colorado to go over Google antitrust probe, Reuters says »

State attorneys general…

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

FB

Facebook

$189.57

-1.29 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:03
11/11/19
11/11
17:03
11/11/19
17:03
Hot Stocks
Franco-Nevada reports 133,219 Gold Equivalent Ounces sold in Q3 »

"Franco-Nevada's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:02
11/11/19
11/11
17:02
11/11/19
17:02
Earnings
Franco-Nevada reports Q3 EPS 54c, may not compare to consensus 27c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ENR

Energizer

$43.11

-0.265 (-0.61%)

16:55
11/11/19
11/11
16:55
11/11/19
16:55
Hot Stocks
Energizer appoints new CFO, Chief Legal Officer, and Chief Accounting Officer »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

16:52
11/11/19
11/11
16:52
11/11/19
16:52
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$78.70

0.22 (0.28%)

, BREW

Craft Brew

$7.33

0.06 (0.83%)

16:51
11/11/19
11/11
16:51
11/11/19
16:51
Hot Stocks
Anheuser-Busch to buy remaining Craft Brew Alliance stake for $16.50 per share »

Today, Craft Brew…

BUD

AB InBev

$78.70

0.22 (0.28%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 27

    Feb

CHAP

Chaparral Energy

$0.90

0.089 (10.99%)

16:47
11/11/19
11/11
16:47
11/11/19
16:47
Earnings
Chaparral Energy reports Q3 EPS ($2.86), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:43
11/11/19
11/11
16:43
11/11/19
16:43
Hot Stocks
DXC Technology says will pursue strategic alternatives for adjacent business »

In Q2 presentation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:41
11/11/19
11/11
16:41
11/11/19
16:41
Earnings
DXC Technology cuts FY20 EPS view to $5.25-$5.75 from $7.00-$7.75 »

Consensus $7.17. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:35
11/11/19
11/11
16:35
11/11/19
16:35
Hot Stocks
Lonestar sees Q4 production 17,200-17,600 BOE/d »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NFE

New Fortress Energy

$15.86

-0.88 (-5.26%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Earnings
New Fortress Energy reports Q3 EPS (30c), consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.